The as-prepared CCM-coated ELP-based nanomicelles can target breast cancer tissues through homologous membrane fusion, which resulted in anchoring IR780 in the cancer cell membranes while directly releasing L-Arg and Rapa-loaded ELP micelles into the cytoplasm (Scheme 1). Here, NR5A1 is linked to breast cancer.